Recovery of functional cytotoxic T lymphocytes during lamivudine therapy by acquiring multi-specificity

Journal of Medical Virology

Volumn 74, Issue 3, 2004, Pages 425-433

  Kondo, Yasuteru ^a   Asabe, Shinichi ^b   Kobayashi, Koju ^c   Shiina, Masaaki ^a,d   Niitsuma, Hirofumi ^a   Ueno, Yoshiyuki ^a   Kobayashi, Tomoo ^e   Shimosegawa, Tooru ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d SENDAI CITY MEDICAL CENTER   (Japan)

^e Furukawa City Hospital   (Japan)

Author keywords

Chronic hepatitis; Epitope; HBV; HLA A24; Tetramer

Indexed keywords

EPITOPE; GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN; HEPATITIS B(E) ANTIGEN; HLA A24 ANTIGEN; LAMIVUDINE; PEPTIDE DERIVATIVE; PERFORIN; TETRAMER;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; ASSAY; CHROMIUM RELEASE ASSAY; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; STAINING; T LYMPHOCYTE; TH1 CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; EPITOPES; FEMALE; HEPATITIS B CORE ANTIGENS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HLA-A ANTIGENS; HUMANS; INTERFERON TYPE II; LAMIVUDINE; MALE; MIDDLE AGED; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 4644308995     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20194     Document Type: Article

References (31)

1. Altman JD, Moss PA, Goulder PJ, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. 1996. Phenotypic analysis of antigen-specific T lymphocytes. Science 274:94-96.
2. Bertoletti A, Ferrari C, Fiaccadori F, Penna A, Margolskee R, Schlicht HJ, Fowler P, Guilhot S, Chisari FV. 1991. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci USA 88:10445-10449.
3. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. 1998. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 102:968-975.
4. Boni C, Penna A, Ogg GS, Bertoletti A, Pilli M, Cavallo C, Cavalli A, Urbani S, Boehme R, Panebianco R, Fiaccadori F, Ferrari C. 2001. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy. Hepatology 33:963-971.
5. Chisari FV, Ferrari C. 1995a. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 13:29-60.
6. Chisari FV, Ferrari C. 1995b. Hepatitis B virus immunopathology. Springer Semin Immunopathol 17:261-281.
7. Dagarag M, Ng H, Lubong R, Effros RB, Yang OO. 2003. Differential impairment of lytic and cytokine functions in senescent human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. J Virol 77:3077-3083.
8. Honkoop P, deMan RA, Niesters HG, Zondervan PE, Schalm SW. 2000. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 32:635-639.
9. Jankovic D, Sher A, Yap G. 2001. Th1/Th2 effector choice in parasitic infection: Decision making by committee. Curr Opin Immunol 13:403-409.
10. Kagi D, Ledermann B, Burki K, Zinkernagel RM, Hengartner H. 1996. Molecular mechanisms of lymphocyte-mediated cytotoxicity and their role in immunological protection and pathogenesis in vivo. Annu Rev Immunol 14:207-232.
11. Kim CY, Tilles JG. 1973. Purification and biophysical characterization of hepatitis B antigen. J Clin Invest 52:1176-1186.
12. Kondo Y, Kobayashi K, Kobayashi T, Shiina M, Ueno Y, Satoh T, Shimosegawa T. 2003. Distribution of the HLA class I allele in chronic hepatitis C and its association with serum ALT level in chronic hepatitis C. Tohoku J Exp Med 201:109-117.
13. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH. 2000. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32:828-834.
14. Malacarne F, Webster GJ, Reignat S, Gotto J, Behboudi S, Burroughs AK, Dusheiko GM, Williams R, Bertoletti A. 2003. Tracking the source of the hepatitis B virus-specific CD8 T cells during lamivudine treatment. J Infect Dis 187:679-682.
15. Missale G, Redeker A, Person J, Fowler P, Guilhot S, Schlicht HJ, Ferrari C, Chisari FV. 1993. HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med 177:751-762.
16. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. 1993. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362:758-761.
17. Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schlicht HJ, Vitiello A, Chesnut R, Person JL, Redeker AG. 1993. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol 150:4659-4671.
18. Ojima T, Niitsuma H, Shan H, Cervantes JG, Nagasaki F, Kikuchi K, Suzuki C, Ueno Y, Ishii M, Kobayashi K, Shimosegawa T. 2001. HBe seroconversion and HBs mutation among Japanese hepatitis B virus carriers. Hepatol Res 20:172-181.
19. Parker KC, Bednarek MA, Coligan JE. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163-175.
20. Penna A, Chisari FV, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, Ferrari C. 1991. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 174:1565-1570.
21. Rehermann B, Fowler P, Sidney J, Person J, Redeker A, Brown M, Moss B, Sette A, Chisari FV. 1995. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 181:1047-1058.
22. Reignat S, Webster GJ, Brown D, Ogg GS, King A, Seneviratne SL, Dusheiko G, Williams R, Maini MK, Bertoletti A. 2002. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med 195:1089-1101.
23. Rico MA, Quiroga JA, Subira D, Castanon S, Esteban JM, Pardo M, Carreno V. 2001. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha. Hepatology 33:295-300.
24. Sobao Y, Sugi K, Tomiyama H, Saito S, Fujiyama S, Morimoto M, Hasuike S, Tsubouchi H, Tanaka K, Takiguch M. 2001. Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*2402, the most common HLA class I allele in East Asia. J Hepatol 34:922-929.
25. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. 2000. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32:803-806.
26. Suzuki F. 2003. Influence of the hepatitis B e antigen/anti-HBe status on the response to lamivudine. Intervirology 46:339-343.
27. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. 1995. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients. Hepatology 21:650-655.
28. Tiollais P, Pourcel C, Dejean A. 1985. The hepatitis B virus. Nature 317:489-495.
29. Tscharke DC, Yewdell JW. 2003. T cells bite the hand that feeds them. Natural Medicines 9:647-648.
30. Welsh RM. 2001. Assessing CD8 T cell number and dysfunction in the presence of antigen. J Exp Med 193:F19-F22.
31. Zhou S, Ou R, Huang L, Price GE, Moskophidis D. 2004. Differential tissue-specific regulation of antiviral CD8+ T-cell immune responses during chronic viral infection. J Virol 78:3578-3600.